National Institute on Drug Abuse; Notice of Closed Meetings, 27504 [06-4401]

Download as PDF 27504 Federal Register / Vol. 71, No. 91 / Thursday, May 11, 2006 / Notices Dated: May 4, 2006. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E6–7178 Filed 5–10–06; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4160–01–S National Institute on Drug Abuse; Notice of Closed Meetings DEPARTMENT OF HEALTH AND HUMAN SERVICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. National Institutes of Health National Institutes of Health National Institute of Child Health and Human Development; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Children’s Study Advisory Committee. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. cchase on PROD1PC60 with NOTICES Name of Committee: National Children’s Study Advisory Committee. Date: May 31–June 1, 2006. Time: 8:30 a.m. to 5 p.m. Agenda: For questions or to register, please call Circle Solutions (703) 902–1339 or visit https://www.circlesolutions.com/ncs/ncsac. Registration deadline is 5/23/06. Agenda will include an update of the Study status and protocol; gene-environment interaction, social-behavioral determinants, and environmental exposure assessment; recruitment and retention; and human subjects activities. Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852. Contact Person: Marion Balsam, MD, Executive Secretary, National Children’s Study Advisory Committee, 6100 Executive Boulevard, Bethesda, MD 20892, 301–594– 9147. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) Dated: May 2, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–4400 Filed 5–10–06; 8:45 am] BILLING CODE 4140–01–M VerDate Aug<31>2005 16:29 May 10, 2006 Jkt 208001 Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Member Conflict Meeting. Date: May 1, 2006. Time: 2:30 p.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Mark R. Green, PhD, Deputy Director, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, (301) 435–1431, mgreen1@nida.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute on Drug Abuse Initial Review Group, Health Services Research Subcommittee. Date: June 6–7, 2006. Time: 8:30 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: The Madison Hotel, 15th & M Streets, NW., Washington, DC 20005. Contact Person: Meenaxi Hiremath, PhD, Health Scientist Administrator, Office of Extramural affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301–402–7964, mh392g@.nih.gov. Name of Committee: National Institute on Drug Abuse Initial Review Group, Medication Development Research Subcommittee. Date: June 6, 2006. Time: 8:30 a.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Housing Center, 1201 15th Street, NW., Washington, DC 20005. Contact Person: Paul A. Coulis, PhD, Health Scientist Administrator, Office of PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Boulevard, Suite 220, Bethesda, MD 20892–8401, 301–443–2105. Name of Committee: National Institute on Drug Abuse Initial Review Group, Treatment Research Subcommittee. Date: June 6–7, 2006. Time: 9 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: The Madison, 1177 15th & M Streets, NW., Washington, DC 20005. Contact Person: Kesinee Nimit, MD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892– 8401, (301)435–1432. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Member Conflict. Date: June 6, 2006. Time: 2 p.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: National Housing Center, 1201 15th Street, NW., Washington, DC 20005. Contact Person: Gerald L. McLaughlin, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., Bethesda, MD 20892–8401, 301–402–6626, gm145a@nih.gov. Name of Committee: National Institute on Drug Abuse Initial Review Group, Training and Career Development Subcommittee. Date: July 18–20, 2006. Time: 9 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue. Bethesda, MD 20814. Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6101 Executive Boulevard, Room 220, MSC 8401, Bethesda, MD 20892–8401, 301–451–4530, el6r@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse national Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs, national Institutes of Health, HHS) Dated: May 2, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–4401 Filed 5–10–06; 8:45am] BILLING CODE 4140–01–M E:\FR\FM\11MYN1.SGM 11MYN1

Agencies

[Federal Register Volume 71, Number 91 (Thursday, May 11, 2006)]
[Notices]
[Page 27504]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-4401]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel, Member Conflict Meeting.
    Date: May 1, 2006.
    Time: 2:30 p.m. to 3:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6101 Executive Boulevard, 
Rockville, MD 20852, (Telephone Conference Call).
    Contact Person: Mark R. Green, PhD, Deputy Director, Office of 
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 
Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-
8401, (301) 435-1431, mgreen1@nida.nih.gov.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute on Drug Abuse Initial 
Review Group, Health Services Research Subcommittee.
    Date: June 6-7, 2006.
    Time: 8:30 a.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: The Madison Hotel, 15th & M Streets, NW., Washington, DC 
20005.
    Contact Person: Meenaxi Hiremath, PhD, Health Scientist 
Administrator, Office of Extramural affairs, National Institute on 
Drug Abuse, National Institutes of Health, DHHS, 6101 Executive 
Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301-402-7964, 
mh392g@.nih.gov.

    Name of Committee: National Institute on Drug Abuse Initial 
Review Group, Medication Development Research Subcommittee.
    Date: June 6, 2006.
    Time: 8:30 a.m. to 4 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Housing Center, 1201 15th Street, NW., 
Washington, DC 20005.
    Contact Person: Paul A. Coulis, PhD, Health Scientist 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, National Institutes of Health, DHHS, 6101 Executive 
Boulevard, Suite 220, Bethesda, MD 20892-8401, 301-443-2105.

    Name of Committee: National Institute on Drug Abuse Initial 
Review Group, Treatment Research Subcommittee.
    Date: June 6-7, 2006.
    Time: 9 a.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: The Madison, 1177 15th & M Streets, NW., Washington, DC 
20005.
    Contact Person: Kesinee Nimit, MD, Health Scientist 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, 
Bethesda, MD 20892-8401, (301)435-1432.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel, Member Conflict.
    Date: June 6, 2006.
    Time: 2 p.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Housing Center, 1201 15th Street, NW., 
Washington, DC 20005.
    Contact Person: Gerald L. McLaughlin, PhD, Scientific Review 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., 
Bethesda, MD 20892-8401, 301-402-6626, gm145a@nih.gov.
    Name of Committee: National Institute on Drug Abuse Initial 
Review Group, Training and Career Development Subcommittee.
    Date: July 18-20, 2006.
    Time: 9 a.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 
Wisconsin Avenue. Bethesda, MD 20814.
    Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, 6101 Executive Boulevard, Room 220, MSC 8401, 
Bethesda, MD 20892-8401, 301-451-4530, el6r@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse national Research Service Awards for Research Training; 
93.279, Drug Abuse Research Programs, national Institutes of Health, 
HHS)

    Dated: May 2, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 06-4401 Filed 5-10-06; 8:45am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.